A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä
A systematic review of the efficacy of live attenuated influenza vaccine upon revaccination of children
Tekijät: Caspard H, Heikkinen T, Belshe RB, Ambrose CS
Kustantaja: TAYLOR & FRANCIS INC
Kustannuspaikka: PHILADELPHIA, PA
Julkaisuvuosi: 2016
Journal: Human Vaccines and Immunotherapeutics
Tietokannassa oleva lehden nimi: HUMAN VACCINES & IMMUNOTHERAPEUTICS
Lehden akronyymi: HUM VACC IMMUNOTHER
Vuosikerta: 12
Numero: 7
Aloitussivu: 1721
Lopetussivu: 1727
Sivujen määrä: 7
ISSN: 2164-5515
eISSN: 2164-554X
DOI: https://doi.org/10.1080/21645515.2015.1115164
Tiivistelmä
Four randomized, double-blind, placebo-controlled studies in 6090 children that investigated the efficacy of live attenuated influenza vaccine (LAIV) upon revaccination of children against laboratory-confirmed cases of influenza in consecutive seasons were reviewed.The efficacy in season 2 of LAIV administered over 2 consecutive seasons was 86.7% (95 % CI: 76.8%, 92.4%) against strains antigenically similar to those contained in the vaccine. The additional efficacy of LAIV administered in season 2 compared to LAIV recipients in season 1 only was 58.4% (28.3%, 75.9%). LAIV administered over 2 consecutive seasons also was more efficacious than was LAIV administered in season 2 only (relative efficacy: 53.9% [17.4%, 74.3%]). Residual efficacy of LAIV administered in season 1 only compared to placebo administered in two consecutive seasons was 56.4% (37.0%, 69.8%). This review did not find any evidence of decreasing efficacy of LAIV when administered during 2 consecutive seasons.
Four randomized, double-blind, placebo-controlled studies in 6090 children that investigated the efficacy of live attenuated influenza vaccine (LAIV) upon revaccination of children against laboratory-confirmed cases of influenza in consecutive seasons were reviewed.The efficacy in season 2 of LAIV administered over 2 consecutive seasons was 86.7% (95 % CI: 76.8%, 92.4%) against strains antigenically similar to those contained in the vaccine. The additional efficacy of LAIV administered in season 2 compared to LAIV recipients in season 1 only was 58.4% (28.3%, 75.9%). LAIV administered over 2 consecutive seasons also was more efficacious than was LAIV administered in season 2 only (relative efficacy: 53.9% [17.4%, 74.3%]). Residual efficacy of LAIV administered in season 1 only compared to placebo administered in two consecutive seasons was 56.4% (37.0%, 69.8%). This review did not find any evidence of decreasing efficacy of LAIV when administered during 2 consecutive seasons.
Turun yliopiston Tutkimustietojärjestelmän portaali